Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease

Women's Health

Volumn 11, Issue 2, 2015, Pages 239-257

  Harvey, Ronée E ^a   Coffman, Kirsten E ^a   Miller, Virginia M ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

estrogen; menopause; pregnancy; sex chromosomes

Indexed keywords

BISOPROLOL; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL; SEX HORMONE; SPIRONOLACTONE; VALSARTAN; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT;

ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTRACEPTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; FEMALE; HEART FAILURE; HORMONAL THERAPY; HUMAN; HYPERTENSION; MALE; MATERNAL HYPERTENSION; MENOPAUSAL SYNDROME; MENOPAUSE; PREGNANCY DIABETES MELLITUS; QT PROLONGATION; REVIEW; RISK FACTOR; SEX CHROMOSOME; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; ESTROGEN THERAPY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; SEX CHROMOSOME ABERRATION; WOMEN'S HEALTH;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; MENOPAUSE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RECEPTORS, ESTROGEN; RISK FACTORS; SEX CHROMOSOME ABERRATIONS; WOMEN'S HEALTH;

EID: 84925151329     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.14.64     Document Type: Review

References (183)

1. Bloom DE, Cafiero ET, Jané-Llopis E et al. The global economic burden of non-communicable diseases. World Economic Forum (2011). www3.weforum.org
2. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
3. Wizemann TM, Pardue ML. Exploring the biological contributions to human health: does sex matter? J. Womens Health Gend. Based Med. 10, 433-439 (2001).
4. Li X. Sex chromosomes and sex chromosome abnormalities. Clin. Lab. Med. 31, 463-479, vii (2011).
5. Bloomer LD, Nelson CP, Eales J et al. Male-specific region of the Y chromosome and cardiovascular risk: phylogenetic analysis and gene expression studies. Arterioscler. Thromb. Vasc. Biol. 33, 1722-1727 (2013).
6. Graves JA. Review: sex chromosome evolution and the expression of sex-specific genes in the placenta. Placenta. 31(Suppl.), S27-S32 (2010).
7. Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat. Rev. Cancer. 4, 617-629 (2004).
8. Ross MT, Grafham DV, Coffey AJ et al. The DNA sequence of the human X chromosme. Nature 434, 325-337 (2005).
9. Agrelo R, Wutz A. X inactivation and disease. Semin. Cell Dev. Biol. 21, 194-200 (2010).
10. Wu H, Luo J, Yu H et al. Cellular resolution maps of X chromosome inactivation: implications for neural development, function, and disease. Neuron 81, 103-119 (2014).
11. Levin JH, Kaler SG. Non-random maternal X-chromosome inactivation associated with PHACES. Clin. Genet. 72, 345-350 (2007).
12. Chung IM, Schwartz SM, Murry CE. Clonal architecture of normal and atherosclerotic aorta: implications for atherogenesis and vascular development. Am. J. Pathol. 152, 913-923 (1998).
13. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am. J. Pathol. 151, 697-705 (1997).
14. Berletch JB, Yang F, Xu J, Carrel L, Disteche CM. Genes that escape from X inactivation. Hum. Genet. 130, 237-245 (2011).
15. Bondy C, Bakalov VK, Cheng C et al. Bicuspid aortic valve and aortic coarctation are linked to deletion of the X chromosome short arm in Turner syndrome. J. Med. Genet. 50, 662-665 (2013).
16. Arnold AP. The organizational-activational hypothesis as the foundation for a unified theory of sexual differentiation of all mammalian tissues. Horm. Behav. 55, 570-578 (2009).
17. Schwend T, Gustafsson JA. False positives in MALDI-TOF detection of ERbeta in mitochondria. Biochem. Biophys. Res. Commun. 343, 707-711 (2006).
18. Yang SH, Liu R, Perez EJ et al. Mitochondrial localization of estrogen receptor beta. Proc. Natl Acad. Sci. USA 101, 4130-4135 (2004).
19. Dan P, Cheung JC, Scriven DR, Moore ED. Epitope-dependent localization of estrogen receptor-alpha, but not -beta, in en face arterial endothelium. Am. J. Physiol. Heart Circ. Physiol. 284, H1295-H1306 (2003).
20. Lizotte E, Grandy SA, Tremblay A, Allen BG, Fiset C. Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. Cell Physiol. Biochem. 23, 75-86 (2009).
21. Kim KH, Young BD, Bender JR. Endothelial estrogen receptor isoforms and cardiovascular disease. Mol. Cell Endocrinol. 389, 65-70 (2014).
22. Bottner M, Thelen P, Jarry H. Estrogen receptor beta: tissue distribution and the still largely enigmatic physiological function. J. Steroid Biochem. Mol. Biol. 139, 245-251 (2014).
23. Christian RC, Liu PY, Harrington S et al. Intimal estrogen receptor (ER)beta, but not ERalpha expression, is correlated with coronary calcification and atherosclerosis in pre- and postmenopausal women. J. Clin. Endocrinol. Metab. 91, 2713-2720 (2006).
24. Liu PY, Christian RC, Ruan M, Miller VM, Fitzpatrick LA. Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J. Clin. Endocrinol. Metab. 90, 1041-1046 (2005).
25. Kuc RE, Carlebur M, Maguire JJ et al. Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. Life Sci. doi:10.1016/j.lfs.2014.02.020 (2014) (Epub ahead of print).
26. Rossouw J, Bray P, Liu J et al. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler. Thromb. Vasc. Biol. 31, 464-469 (2011).
27. Saltiki K, Mantzou E, Doukas C et al. Estrogen receptor beta gene variants may be associated with more favorable metabolic profile in postmenopausal women undergoing coronary angiography. Exp. Clin. Endocrinol. Diabetes. 117, 610-615 (2009).
28. Duckles SP, Miller VM. Hormonal modulation of endothelial NO production. Pflugers Arch. 459, 841-851 (2010).
29. Sudhir K, Chou TM, Chatterjee K et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96, 3774-3777 (1997).
30. Bednarek-Tupikowska G, Tworowska-Bardzinska U, Tupikowski K. Effects of estrogen and estrogen-progesteron on serum nitric oxide metabolite concentrations in post-menopausal women. J. Endocrinol Invest. 31, 877-881 (2008).
31. Post WS, Goldschmidt-Clermont PJ, Wilhide CC et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc. Res. 43, 985-991 (1999).
32. Liu MY, Hattori Y, Sato A et al. Ovariectomy attenuates hyperpolarization and relaxation mediated by endothelium-derived hyperpolarizing factor in female rat mesenteric artery: a concomitant decrease in connexin-43 expression. J. Cardiovasc. Pharmacol. 40, 938-948 (2002).
33. Nawate S, Fukao M, Sakuma I et al. Reciprocal changes in endothelium-derived hyperpolarizing factor- and nitric oxide-system in the mesenteric artery of adult female rats following ovariectomy. Br. J. Pharmacol. 144, 178-189 (2005).
34. Villar IC, Hobbs AJ, Ahluwalia A. Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor. J. Endocrinol. 197, 447-462 (2008).
35. Sakuma I, Liu MY, Sato A et al. Endothelium-dependent hyperpolarization and relaxation in mesenteric arteries of middle-aged rats: influence of oestrogen. Br. J. Pharmacol. 135, 48-54 (2002).
36. Luksha L, Poston L, Gustafsson JA, Hultenby K, Kublickiene K. The oestrogen receptor beta contributes to sex related differences in endothelial function of murine small arteries via EDHF. J. Physiol. 577, 945-955 (2006).
37. Luksha L, Agewall S, Kublickiene K. Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 202, 330-344 (2009).
38. Prossnitz ER, Barton M. Estrogen biology: new insights into GPER function and clinical opportunities. Mol. Cell. Endocrinol. 389, 71-83 (2014).
39. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625-1630 (2005).
40. Geraldes P, Sirois MG, Bernatchez PN, Tanguay JF. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 22, 1585-1590 (2002).
41. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ. Res. 93, 399-405 (2003).
42. Miller VM, Duckles SP. Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60, 210-241 (2008).
43. Dai-Do D, Espinosa E, Liu G et al. 17 beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males. Cardiovasc. Res. 32, 980-985 (1996).
44. Kappert K, Caglayan E, Huntgeburth M et al. 17Beta-estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level. Am. J. Physiol. Heart Circ. Physiol. 290, H538-H546 (2006).
45. Li F, Yu X, Szynkarski CK et al. Activation of GPER induces differentiation and inhibition of coronary artery smooth muscle cell proliferation. PLoS ONE 8, e64771 (2013).
46. Jiang X, Zhang Y, Hou D et al. 17beta-estradiol inhibits oleic acid-induced rat VSMC proliferation and migration by restoring PGC-1alpha expression. Mol. Cell Endocrinol. 315, 74-80 (2010).
47. Watanabe T, Akishita M, Nakaoka T et al. Caveolin-1, Id3a and two LIM protein genes are upregulated by estrogen in vascular smooth muscle cells. Life Sci. 75, 1219-1229 (2004).
48. Lee HW, Eghbali-Webb M. Estrogen enhances proliferative capacity of cardiac fibroblasts by estrogen receptor- and mitogen-activated protein kinase-dependent pathways. J. Mol. Cell Cardiol. 30, 1359-1368 (1998).
49. Kararigas G, Bito V, Tinel H et al. Transcriptome characterization of estrogen-treated human myocardium identifies myosin regulatory light chain interacting protein as a sex-specific element influencing contractile function. J. Am. Coll. Cardiol. 59, 410-417 (2012).
50. Thomas P, Pang Y. Protective actions of progesterone in the cardiovascular system: potential role of membrane progesterone receptors (mPRs) in mediating rapid effects. Steroids 78, 583-588 (2013).
51. Cutini PH, Massheimer VL. Role of progesterone on the regulation of vascular muscle cells proliferation, migration and apoptosis. Steroids 75, 355-361 (2010).
52. Barbagallo M, Dominguez LJ, Licata G et al. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension 37, 142-147 (2001).
53. Naftolin F, Horvath TL, Jakab RL et al. Aromatase immunoreactivity in axon terminals of the vertebrate brain. An immunocytochemical study on quail, rat, monkey and human tissues. Neuroendocrinology 63, 149-155 (1996).
54. Bell JR, Bernasochi GB, Varma U, Raaijmakers AJ, Delbridge LM. Sex and sex hormones in cardiac stress - mechanistic insights. J. Steroid Biochem. Mol. Biol. 137, 124-135 (2013).
55. Harada N, Sasano H, Murakami H et al. Localized expression of aromatase in human vascular tissues. Circ. Res. 84, 1285-1291 (1999).
56. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J. Clin. Endocrinol. Metab. 90, 2708-2711 (2005).
57. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 351, 1425-1427 (1998).
58. Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol. Metab. Clin. North Am. 40, 419-432, ix (2011).
59. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J. Am. Coll. Cardiol. 53, 221-231 (2009).
60. st century. J. Clin. Invest. 118, 1330-1343 (2008).
61. Brito MB, Nobre F, Vieira CS. Hormonal contraception and cardiovascular system. Arq. Bras. Cardiol. 96, e81-e89 (2011).
62. Cardoso F, Polonia J, Santos A, Silva-Carvalho J, Ferreira-de-Almeida J. Low-dose oral contraceptives and 24-hour ambulatory blood pressure. Int. J. Gynaecol. Obstet. 59, 237-243 (1997).
63. Narkiewicz K, Graniero GR, D'Este D et al. Ambulatory blood pressure in mild hypertensive women taking oral contraceptives. A case-control study. Am. J. Hypertens. 8, 249-253 (1995).
64. Gordon MS, Chin WW, Shupnik MA. Regulation of angiotensinogen gene expression by estrogen. J. Hypertens. 10, 361-366 (1992).
65. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 61, 166-171 (1996).
66. Giribela CR, Melo NR, Silva RC et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 86, 35-41 (2012).
67. Wu CQ, Grandi SM, Filion KB et al. Drospirenone-containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review. BJOG 120, 801-810 (2013).
68. Sedlak T, Shufelt C, Iribarren C, Lyon LL, Bairey Merz CN. Oral contraceptive use and the ECG: evidence of an adverse QT effect on corrected QT interval. Ann. Noninvasive Electrocardiol. 18, 389-398 (2013).
69. Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J. Hypertens. 15, 1063-1068 (1997).
70. Lizarelli PM, Martins WP, Vieira CS et al. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception 79, 35-40 (2009).
71. Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 86, 606-621 (2012).
72. Plu-Bureau G, Hugon-Rodin J, Maitrot-Mantelet L, Canonico M. Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract. Res. Clin. Endocrinol. Metab. 27, 35-45 (2013).
73. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N. Engl. J. Med. 366, 2257-2266 (2012).
74. Chapman AB, Abraham WT, Zamudio S et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 54, 2056-2063 (1998).
75. Creasy RK, Resnik R, Iams JD. Creasy and Resnik's Maternal-Fetal Medicine: Principles And Practice. Saunders/Elsevier, PA, USA (2014).
76. Carbillon L, Uzan M, Uzan S. Pregnancy, vascular tone, and maternal hemodynamics: a crucial adaptation. Obstet. Gynecol. Surv. 55, 574-581 (2000).
77. Charlton F, Tooher J, Rye KA, Hennessy A. Cardiovascular risk, lipids and pregnancy: preeclampsia and the risk of later life cardiovascular disease. Heart Lung Circ. 23, 203-212 (2014).
78. Wenger NK. Recognizing pregnancy-associated cardiovascular risk factors. Am. J. Cardiol. 113, 406-409 (2014).
79. Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular disease. Cardiovasc. Res. 101, 579-586 (2014).
80. Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch. Gynecol. Obstet. 285, 1553-1562 (2012).
81. Al-Jameil N, Aziz Khan F, Fareed Khan M, Tabassum H. A brief overview of preeclampsia. J Clin. Med. Res. 6, 1-7 (2014).
82. Garovic VD, August P. Preeclampsia and the future risk of hypertension: the pregnant evidence. Curr. Hypertens. Rep. 15, 114-121 (2013).
83. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308, 1592-1594 (2005).
84. Valdiviezo C, Garovic VD, Ouyang P. Preeclampsia and hypertensive disease in pregnancy: their contributions to cardiovascular risk. Clin. Cardiol. 35, 160-165 (2012).
85. Roberts JM, Hubel CA. Pregnancy: a screening test for later life cardiovascular disease. Womens Health Issues 20, 304-307 (2010).
86. Cusimano MC, Pudwell J, Roddy M, Cho CK, Smith GN. The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am. J. Obstet. Gynecol. 210, 438 e431-e439 (2014).
87. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 335, 974 (2007).
88. Kim C. Gestational diabetes mellitus and risk of future maternal cardiovascular disease. Expert Rev. Cardiovasc. Ther. 8, 1639-1641 (2010).
89. Sokup A, Goralczyk B, Goralczyk K, Rosc D. Triglycerides as an early pathophysiological marker of endothelial dysfunction in nondiabetic women with a previous history of gestational diabetes. Acta. Obstet. Gynecol. Scand. 91, 182-188 (2012).
90. Li J, LaMarca B, Reckelhoff JF. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. Am. J. Physiol. Heart Circ. Physiol. 303, H1-H8 (2012).
91. Fang SH, Yan H, Dang SN et al. Relationship between female menopause and hypertension/isolated systolic hypertension in rural districts of Hanzhong in Shaanxi province. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 35, 422-426 (2013).
92. Gierach GL, Pfeiffer RM, Patel DA et al. Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages. Menopause 21, 592-601 (2014).
93. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 65, 161-166 (2010).
94. Hart EC, Charkoudian N, Miller VM. Sex, hormones and neuroeffector mechanisms. Acta Physiol. 203, 155-165 (2011).
95. Park JK, Lim YH, Kim KS et al. Body fat distribution after menopause and cardiovascular disease risk factors: Korean National Health and Nutrition Examination Survey 2010. J. Womens Health 22, 587-594 (2013).
96. Reddy Kilim S, Chandala SR. A comparative study of lipid profile and oestradiol in pre- and post-menopausal women. J. Clin. Diagn. Res. 7, 1596-1598 (2013).
97. Goldstein LB, Adams R, Alberts MJ et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 113, e873-e923 (2006).
98. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
99. Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 20, 342-353 (2013).
100. Schierbeck LL, Rejnmark L, Tofteng CL et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 345, e6409 (2012).
101. Abelin AP, Nunes CM, Camazzola FE, Santos RP. Doubts from an open label trial. In: BMJ (2012). www.bmj.com
102. Schroll J, Lundh A. Was the composite outcome specified in the original protocol? BMJ 345, e8144; author reply e8164 (2012).
103. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N. Engl. J. Med. 349, 523-534 (2003).
104. Wild RA, Wu C, Curb JD et al. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 20, 254-260 (2013).
105. Harman SM, Black DM, Naftolin F et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women in the Kronos Early Estrogen Prevention Study (KEEPS): a randomized controlled trial. Ann. Intern. Med. (2014) (In press).
106. Bushnell C, McCullough LD, Awad IA et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 45, 1545-1588 (2014).
107. Main C, Knight B, Moxham T et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 4, CD002229 (2013).
108. Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. Prescribing menopausal hormone therapy: an evidence-based approach. Int. J. Womens Health 6, 47-57 (2014).
109. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 15, 217-228 (2012).
110. Hodis HN, Mack WJ. A 'window of opportunity:' the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res. 1379, 244-252 (2011).
111. Abramson BL, Melvin RG. Cardiovascular risk in women: focus on hypertension. Can. J. Cardiol. 30, 553-559 (2014).
112. Gotto AM Jr and Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am. J. Cardiol. 110, A3-A14 (2012).
113. Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1-S45 (2014).
114. Jennings GL, Touyz RM. Hypertension guidelines: more challenges highlighted by Europe. Hypertension 62, 660-665 (2013).
115. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 124, 2145-2154 (2011).
116. Goodarzi MO, Li X, Krauss RM, Rotter JI, Chen YD. Relationship of sex to diabetes risk in statin trials. Diabetes Care 36, e100-e101 (2013).
117. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature 509, 282-283 (2014).
118. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 129, e28-e292 (2014).
119. Daugherty SL, Masoudi FA, Zeng C et al. Sex differences in cardiovascular outcomes in patients with incident hypertension. J. Hypertens. 31, 271-277 (2013).
120. Gu Q, Burt VL, Paulose-Ram R, Dillon CF. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am. J. Hypertens. 21, 789-798 (2008).
121. Banegas JR, Segura J, de la Sierra A et al. Gender differences in office and ambulatory control of hypertension. Am. J. Med. 121, 1078-1084 (2008).
122. Daugherty SL, Masoudi FA, Ellis JL et al. Age-dependent gender differences in hypertension management. J. Hypertens. 29, 1005-1011 (2011).
123. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507-520 (2014).
124. Peters SA, Huxley RR, Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. Stroke 44, 2394-2401 (2013).
125. Turnbull F, Woodward M, Neal B et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur. Heart J. 29, 2669-2680 (2008).
126. Dowling NM, Gleason CE, Manson JE et al. Characterization of vascular disease risk in postmenopausal women and its association with cognitive performance. PLoS ONE 8, e68741 (2013).
127. Basu R, Franzini L, Krueger PM, Lairson DR. Gender disparities in medical expenditures attributable to hypertension in the United States. Womens Health Issues 20, 114-125 (2010).
128. Gall SL, Donnan G, Dewey HM et al. Sex differences in presentation, severity, and management of stroke in a population-based study. Neurology 74, 975-981 (2010).
129. Santalucia P, Pezzella FR, Sessa M et al. Sex differences in clinical presentation, severity and outcome of stroke: results from a hospital-based registry. Eur. J. Intern Med. 24, 167-171 (2013).
130. Jauch EC, Saver JL, Adams HP Jr et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44, 870-947 (2013).
131. Reeves M, Bhatt A, Jajou P, Brown M, Lisabeth L. Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis. Stroke 40, 1743-1749 (2009).
132. Towfighi A, Markovic D, Ovbiagele B. Sex differences in revascularization interventions after acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 22, e347-353 (2013).
133. de Ridder I, Dirks M, Niessen L, Dippel D. Unequal access to treatment with intravenous alteplase for women with acute ischemic stroke. Stroke 44, 2610-2612 (2013).
134. Gall SL, Tran PL, Martin K, Blizzard L, Srikanth V. Sex differences in long-term outcomes after stroke: functional outcomes, handicap, and quality of life. Stroke 43, 1982-1987 (2012).
135. Lorenzano S, Ahmed N, Falcou A et al. Does sex influence the response to intravenous thrombolysis in ischemic stroke?: answers from safe implementation of treatments in Stroke-International Stroke Thrombolysis Register. Stroke 44, 3401-3406 (2013).
136. Ovbiagele B, Markovic D, Towfighi A. Recent age- and gender-specific trends in mortality during stroke hospitalization in the United States. Int. J. Stroke 6, 379-387 (2011).
137. Nabel EG, Braunwald E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54-63 (2012).
138. Shaw LJ, Bairey Merz CN, Pepine CJ et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J. Am. Coll. Cardiol. 47, S4-S20 (2006).
139. Bairey Merz CN, Shaw LJ, Reis SE et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J. Am. Coll. Cardiol. 47, S21-S29 (2006).
140. McSweeney JC, Cody M, O'Sullivan P et al. Women's early warning symptoms of acute myocardial infarction. Circulation 108, 2619-2623 (2003).
141. Douglas PS, Ginsburg GS. The evaluation of chest pain in women. N. Engl. J. Med. 334, 1311-1315 (1996).
142. Eastwood JA, Johnson BD, Rutledge T et al. Anginal symptoms, coronary artery disease, and adverse outcomes in Black and White women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. J. Womens Health 22, 724-732 (2013).
143. Tamura A, Naono S, Torigoe K et al. Gender differences in symptoms during 60-second balloon occlusion of the coronary artery. Am. J. Cardiol. 111, 1751-1754 (2013).
144. Sharaf BL, Pepine CJ, Kerensky RA et al. Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). Am. J. Cardiol. 87, 937-941; A933 (2001).
145. Jug B, Gupta M, Papazian J et al. Diagnostic performance of 64-slice multidetector coronary computed tomographic angiography in women. J. Nucl. Cardiol. 19, 1154-1161 (2012).
146. Kohli P, Gulati M. Exercise stress testing in women: going back to the basics. Circulation. 122, 2570-2580 (2010).
147. Levisman JM, Aspry K, Amsterdam EA. Improving the positive predictive value of exercise testing in women for coronary artery disease. Am. J. Cardiol. 110, 1619-1622 (2012).
148. Kwok Y, Kim C, Grady D, Segal M, Redberg R. Meta-analysis of exercise testing to detect coronary artery disease in women. Am. J. Cardiol. 83, 660-666 (1999).
149. Marwick TH, Anderson T, Williams MJ et al. Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. J. Am. Coll. Cardiol. 26, 335-341 (1995).
150. Wierzbowska-Drabik K, Roszczyk N, Sobczak M et al. Effect of sex on the diagnostic efficacy of dobutamine stress echocardiography with early atropine administration in the detection of coronary artery disease. Pol. Arch. Med. Wewn. 124, 105-113 (2014).
151. Rosenmann D, Mogilevski Y, Amit G, Davrath LR, Tzivoni D. High-frequency QRS analysis improves the specificity of exercise ECG testing in women referred for angiography. J. Electrocardiol. 46, 19-26 (2013).
152. Amanullah AM, Berman DS, Hachamovitch R et al. Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT. Am. J. Cardiol. 80, 132-137 (1997).
153. Hachamovitch R, Berman DS, Kiat H et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. J. Am. Coll. Cardiol. 28, 34-44 (1996).
154. Iskandar A, Limone B, Parker MW et al. Gender differences in the diagnostic accuracy of SPECT myocardial perfusion imaging: a bivariate meta-analysis. J. Nucl. Cardiol. 20, 53-63 (2013).
155. Greenwood JP, Motwani M, Maredia N et al. Comparison of cardiovascular magnetic resonance and single-photon emission computed tomography in women with suspected coronary artery disease from the clinical evaluation of magnetic resonance imaging in coronary heart disease (CE-MARC) trial. Circulation 129, 1129-1138 (2014).
156. El-Menyar A, Ahmed E, Albinali H et al. Mortality trends in women and men presenting with acute coronary syndrome: insights from a 20-year registry. PLoS ONE 8, e70066 (2013).
157. East MA, Jollis JG, Nelson CL, Marks D, Peterson ED. The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter? J. Am. Coll. Cardiol. 41, 949-954 (2003).
158. Wang TK, Ramanathan T, Stewart R, Gamble G, White H. Higher mortality in women undergoing coronary artery bypass grafting. N. Z. Med. J. 126, 25-31 (2013).
159. Pendyala LK, Torguson R, Loh JP et al. Comparison of adverse outcomes after contemporary percutaneous coronary intervention in women versus men with acute coronary syndrome. Am. J. Cardiol. 111, 1092-1098 (2013).
160. Kornowski R, Vaknin-Assa H, Assali A et al. A comparative analysis of major clinical outcomes with drug-eluting stents versus bare metal stents in male versus female patients. EuroIntervention 7, 1051-1059 (2012).
161. Anderson ML, Peterson ED, Brennan JM et al. Short- and long-term outcomes of coronary stenting in women versus men: results from the National Cardiovascular Data Registry Centers for Medicare & Medicaid services cohort. Circulation 126, 2190-2199 (2012).
162. Bugiardini R, Yan AT, Yan RT et al. Factors influencing underutilization of evidence-based therapies in women. Eur. Heart J. 32, 1337-1344 (2011).
163. Koopman C, Vaartjes I, Heintjes EM et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur. Heart J. 34, 3198-3205 (2013).
164. Greiten LE, Holditch SJ, Arunachalam SP, Miller VM. Should there be sex-specific criteria for the diagnosis and treatment of heart failure? J. Cardiovasc. Transl. Res. 7, 139-155 (2014).
165. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr. Opin. Cardiol. 26, 562-568 (2011).
166. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur. Heart J. 32, 670-679 (2011).
167. Go AS, Mozaffarian D, Roger VL et al. Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 129, 399-410 (2014).
168. Rautaharju PM, Zhang ZM, Haisty WK Jr et al. Electrocardiographic predictors of incident heart failure in men and women free from manifest cardiovascular disease (from the Atherosclerosis Risk in Communities [ARIC] study). Am. J. Cardiol. 112, 843-849 (2013).
169. Gori M, Lam CS, Gupta DK et al. Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur. J. Heart Fail. 16, 535-542 (2014).
170. Goto T, Ohte N, Fukuta H et al. Relationship between effective arterial elastance, total vascular resistance, and augmentation index at the ascending aorta and left ventricular diastolic function in older women. Circ. J. 77, 123-129 (2013).
171. Corra U, Mezzani A, Giordano A et al. Peak oxygen consumption and prognosis in heart failure: 14 mL/kg/min is not a "gender-neutral" reference. Int. J. Cardiol. 167, 157-161 (2013).
172. Barsheshet A, Brenyo A, Goldenberg I, Moss AJ. Sex-related differences in patients' responses to heart failure therapy. Nat. Rev. Cardiol. 9, 234-242 (2012).
173. Shah RU, Chang TI, Fonarow GC. Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail. Clin. 9, 79-92 (2013).
174. Wise FM, Patrick JM. Cardiac rehabilitation outcomes in women with chronic heart failure: mood, fitness, and exercise safety. J. Cardiopulm. Rehabil. Prev. 32, 78-84 (2012).
175. Schuchert A, Muto C, Maounis T et al. Gender-related safety and efficacy of cardiac resynchronization therapy. Clin. Cardiol. 36, 683-690 (2013).
176. Zabarovskaja S, Gadler F, Braunschweig F et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace 14, 1148-1155 (2012).
177. Xu YZ, Friedman PA, Webster T et al. Cardiac resynchronization therapy: do women benefit more than men? J. Cardiovasc. Electrophysiol. 23, 172-178 (2012).
178. Mooyaart EA, Marsan NA, van Bommel RJ et al. Comparison of long-term survival of men versus women with heart failure treated with cardiac resynchronization therapy. Am. J. Cardiol. 108, 63-68 (2011).
179. Cheng A, Gold MR, Waggoner AD et al. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 9, 736-741 (2012).
180. Fairweather D, Cooper LT Jr, Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr. Probl. Cardiol. 38, 7-46 (2013).
181. Farasat SM, Bolger DT, Shetty V et al. Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction. Am. J. Cardiol. 105, 229-234 (2010).
182. van Veldhuisen DJ, Cohen-Solal A, Bohm M et al. Betablockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J. Am. Coll. Cardiol. 53, 2150-2158 (2009).
183. Iellamo F, Volterrani M, Caminiti G et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J. Am. Coll. Cardiol. 56, 1310-1316 (2010).